Trials / Completed
CompletedNCT01561521
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Akorn, Inc. · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AKF-1 | 1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period |
| DRUG | AKF-1 | 1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period |
| DRUG | AKF-1 | 1 drop 0% in each eye at 2 separate times during a 14 day period |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2012-03-23
- Last updated
- 2013-07-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01561521. Inclusion in this directory is not an endorsement.